BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21073062)

  • 21. Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10-45 years.
    Tregnaghi MW; Voelker R; Santos-Lima E; Zambrano B
    Vaccine; 2010 Apr; 28(20):3595-601. PubMed ID: 20189492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents.
    Schiff GM; Sherwood JR; Zeldis JB; Krause DS
    J Adolesc Health; 1995 Jan; 16(1):12-7. PubMed ID: 7742331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses.
    Heininger U; ; ; Sänger R; Jacquet JM; Schuerman L
    Vaccine; 2007 Jan; 25(6):1055-63. PubMed ID: 17049692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Poor efficacy of intradermal administration of recombinant hepatitis B virus immunization in HIV-infected individuals who fail to respond to intramuscular administration of hepatitis B virus vaccine.
    Shafran SD; Mashinter LD; Lindemulder A; Taylor GD; Chiu I
    HIV Med; 2007 Jul; 8(5):295-9. PubMed ID: 17561875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants.
    Olivier C; Belohradsky BH; Stojanov S; Bonnet E; Petersen G; Liese JG
    Vaccine; 2008 Jun; 26(25):3142-52. PubMed ID: 18502545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
    Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L
    Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections.
    Schmitt HJ; Knuf M; Ortiz E; Sänger R; Uwamwezi MC; Kaufhold A
    J Pediatr; 2000 Sep; 137(3):304-12. PubMed ID: 10969252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, single-blind comparison of the immunogenicity and reactogenicity of 20 micrograms and 10 micrograms doses of hepatitis B vaccine in adolescents.
    Poovorawan Y; Pongpunlert W; Theamboonlers A; Vimolgej L; Chumdermpadetsuk S; Vandepapeliere P; Safary A
    Southeast Asian J Trop Med Public Health; 1993 Jun; 24(2):255-9. PubMed ID: 8266226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A two-dose schedule for combined hepatitis A and B vaccination in children aged 6-15 years.
    Kurugöl Z; Mutlubaş F; Ozacar T
    Vaccine; 2005 Apr; 23(22):2876-80. PubMed ID: 15780736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine in haemodialysis patients.
    Fujiyama S; Yoshida K; Sato T; Shimada H; Deguchi T
    Hepatogastroenterology; 1990 Dec; 37 Suppl 2():140-4. PubMed ID: 2150664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials.
    Tielemans CL; Vlasak J; Kosa D; Billiouw JM; Verpooten GA; Mezei I; Ryba M; Peeters PC; Mat O; Jadoul MY; Polakovic V; Dhaene M; Treille S; Kuriyakose SO; Leyssen M; Houard SA; Surquin M
    Vaccine; 2011 Feb; 29(6):1159-66. PubMed ID: 21167859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative efficacy of two dosages of recombinant hepatitis B vaccine in healthy adolescents in India.
    Velu V; Nandakumar S; Shanmugam S; Shankar EM; Thangavel S; Kulkarni PS; Thyagarajan SP
    Pediatr Infect Dis J; 2007 Nov; 26(11):1038-41. PubMed ID: 17984812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reactogenicity and immunogenicity of a recombinant hepatitis B vaccine compared with a plasma-derived vaccine in young adults.
    Just M; Berger R; Just V
    Postgrad Med J; 1987; 63 Suppl 2():121-3. PubMed ID: 3317346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus.
    Van Der Meeren O; Peterson JT; Dionne M; Beasley R; Ebeling PR; Ferguson M; Nissen MD; Rheault P; Simpson RW; De Ridder M; Crasta PD; Miller JM; Trofa AF
    Hum Vaccin Immunother; 2016 Aug; 12(8):2197-2203. PubMed ID: 27123743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults.
    Levie K; Gjorup I; Skinhøj P; Stoffel M
    Scand J Infect Dis; 2002; 34(8):610-4. PubMed ID: 12238579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults.
    Halperin SA; McNeil S; Langley JM; Smith B; MacKinnon-Cameron D; McCall-Sani R; Heyward WL; Martin JT
    Vaccine; 2012 Aug; 30(36):5445-8. PubMed ID: 22704926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants.
    Vesikari T; Martin JC; Liss CL; Liska V; Schödel FP; Bhuyan PK
    Pediatr Infect Dis J; 2011 Jul; 30(7):e109-13. PubMed ID: 21552183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Study on the immuno-effects and influencing factors of Chinese hamster ovary (CHO) cell hepatitis B vaccine among adults, under different dosages].
    Zhang W; Lin CY; Han LL; Li LQ; Gao P; Lin H; Gong XH; Huang F; Tang YQ; Ma JX; Zhang HY; Wang C; Yang P; Li H; Sun MP; He X; Pang XH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Jul; 31(7):767-70. PubMed ID: 21162840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy neonates.
    Minervini G; McCarson BJ; Reisinger KS; Martin JC; Stek JE; Atkins BM; Nadig KB; Liska V; Schödel FP; Bhuyan PK
    Vaccine; 2012 Feb; 30(8):1476-80. PubMed ID: 22227229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls.
    Schmeink CE; Bekkers RL; Josefsson A; Richardus JH; Berndtsson Blom K; David MP; Dobbelaere K; Descamps D
    Vaccine; 2011 Nov; 29(49):9276-83. PubMed ID: 21856349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.